

Henry Ford Health System

Henry Ford Health System Scholarly Commons

Ophthalmology Articles

Ophthalmology and Eye Care Services

4-8-2021

Re: Modi et al.: Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens (Ophthalmology. 2021;128:197-207)

Fuxiang Zhang

Follow this and additional works at: https://scholarlycommons.henryford.com/ophthalmology_articles



Correspondence

Re: Modi et al.: Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens
(*Ophthalmology*. 2021;128:197–207)

TO THE EDITOR: With great interest, I read the article by Modi et al.¹ Of note, that was a prospective, multicenter, nonrandomized, parallel-group, assessor-masked, confirmatory trial approved by the US Food and Drug Administration to evaluate the effectiveness and safety of the TNFT00 lens. Just wonder why SN60AT was used for the control group, as opposed to the SN60WF. The SN60WF is more comparable than the SN60AT, which is not an aspheric intraocular lens. As we know, aberration plays a significant role for visual quality. Both the TNFT00 and SN60WF have built-in negative spherical aberration to compensate for the positive corneal aberration, but the SN60AT does not.

FUXIANG ZHANG, MD

Henry Ford Health System, Taylor, Michigan

Disclosure(s):

All authors have completed and submitted the ICMJE disclosures form. The author has no proprietary or commercial interest in any materials discussed in this article.

Available online: ■■■.

Correspondence:

Fuxiang Zhang, MD, Henry Ford Health System, Taylor, MI 48202. E-mail: fzhang1@hfhs.org.

Reference

1. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. *Ophthalmology*. 2021;128:197–207.